4Tan K,Brayshaw N,Tomaszewski K,et al.Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities[J].J Clin Pharmacol,2006,46(2):235-243.
5Imataki O,Ohnishi H,Kitanaka A,et al.Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population[J].Int J Hematol,2008,88(1):3-6.
二级参考文献29
1Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med, 2011,183:96-128.
2Kappe R. Antifungal activity of the new azole UK-109,496 (voriconazole)[J].{H}MYCOSES,1999,(Suppl 2):83-86.
3Herbrecht R,Denning DW,Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].{H}New England Journal of Medicine,2002,(06):408-415.
4Walsh TJ,Lutsar I,Driscoll T. Voriconazole in the treatment of aspergillosis,scedosporiosis and other invasive fungal infections in children[J].{H}Pediatric Infectious Disease Journal,2002,(03):240-248.
5Purkins L,Wood N,Ghahramani P. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].{H}Antimicrobial Agents and Chemotherapy,2002,(08):2546-2553.
6Ally R,Schurmann D,Kreisel W. A randomized,doubleblind,double-dummy,muhicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients[J].{H}Clinical Infectious Diseases,2001,(09):1447-1454.
7Walsh TJ,Karlsson MO,Driscoll T. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration[J].{H}Antimicrobial Agents and Chemotherapy,2004,(06):2166-2172.
9Lazarus HM,Blumer J L,Yanovich S. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection:A dose escalation study[J].{H}Journal of Clinical Pharmacology,2002,(04):395-402.
10Ghannoum MA,Kuhn DM. Voriconazole-Better chances for patients with invasive mycoses[J].{H}European Journal of medical Reseasarch,2002,(05):242-256.
2Ben-AmiR, Lewis RE, Kontoyiannis DP. Immunocompro-mised hosts. Immunopharmacology of modem antifungals[J]. Clin Infect Dis,2008,47(2) 226.
3PattersOn TF,Boueher HW, Herbrecht R, et al. Strategy Following Voriconazole versus amphotericin B therapy wiith other Iicense anti- funga] therapy for primary treatment of invasive asperllosis*.Impact of other therapies outcome [J]. Clin Infect Dis, 2005, 41 (10). 1448-1452.
4Driscoll TA, Frarjoul H, Nemecek ER, et al. Comparison of pharma- cokinetics and safety of voriconazole intravenous-to-ora| switch in im- munocompromised adolescents healthy adults[J]. Antimierob Agents Chemother,2011,55(12) ,5780-5789.
5Diekema DJ ,Messer SA,Hollis RJ,et al. A global evaluation of vori- conazole activity tested against recent clinical isolates of Candida spp [J]. Diagn Microbiol Inject Dis,2009,63(2):233-236.
6Miyakis S,Van Hal SJ,Ray J,et al. Voriconazole concentrations and outcome of invasive fungal infections[J]. Clin Microbiol Infect, 2010, 16(7) .927-933.
8Eiden C, Peynere H, Cociglio M, et al. Adverse effects of voriconazole:analysis of the French pharmacovigilance database [J]. Ann Pharmacot her, 2007,41 (5) : 755.
9Miller DD,t.k)wen EW, Nguyen JC, et al. Melanoma associated with long term voriconazole therapy: A new man if estation oi" chronic pho- tosensitivity[J]. Arch Dermatol, 2010,146 (3) : 300.
10Ryan R, Riabi KS, Philip R, et al. Voriconazole-assoeiated phototoxicity[J]. Dermatol ()nline J, 2011,17 ( 2 ) : 15.
